[1] |
刘怡茜, 仇红霞, 李建勇, 等. 非霍奇金淋巴瘤治疗后继发急性髓系白血病[J]. 中国实验血液学杂志, 2009, 17(3):756-759.
|
[2] |
RASHIDI A, FISHER S I. Therapy-related acute promyelocytic leukemia:a systematic review[J]. Med Oncol, 2013, 30(3):625.
|
[3] |
BODDU P C, KANTARJIAN H M, RAVANDI F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach[J]. Cancer, 2017, 123(16):3050-3060.
DOI
PMID
|
[4] |
MAUNG S W, BURKE C, HAYDE J, et al. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia(t-MDS/AML) in Irish patients:a single centre experience[J]. Hematology, 2017, 22(6):341-346.
|
[5] |
RENELLA R, VERKOOIJEN H M, FIORETTA G, et al. Increased risk of acute myeloid leukaemia after treatment for breast cancer[J]. Breast, 2006, 15(5):614-619.
PMID
|
[6] |
WONG T N, RAMSINGH G, YOUNG A L, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia[J]. Nature, 2015, 518(7540):552-555.
|
[7] |
DAYYANI F, KANTARJIAN H, O'BRIEN S, et al. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy[J]. Cancer, 2011, 117(1):110-115.
DOI
PMID
|
[8] |
张风红, 吴倩, 尹佳, 等. 慢性髓性白血病酪氨酸激酶抑制剂治疗过程中继发Ph染色体阴性急性早幼粒细胞白血病一例[J]. 中华血液学杂志, 2021, 42(3):259.
|
[9] |
WAKIM J J, TIRADO C A, DOWELL J, et al. The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia[J]. Cancer Genet, 2012, 205(3):124-127.
|
[10] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2):277-292.
|
[11] |
ZHU C, MA X, HU Y, et al. Safety and efficacy profile of lenvatinib in cancer therapy:a systematic review and meta-analysis[J]. Oncotarget, 2016, 7(28):44545-44557.
|
[12] |
CHEN S J, CHEN Z, CHEN A, et al. Occurrence of distinct PML-RAR-alpha fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction[J]. Oncogene, 1992, 7(6):1223-1232.
PMID
|